Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sedana Medical AB ( (SE:SEDANA) ) has shared an announcement.
Sedana Medical AB will publish its interim report for the fourth quarter of 2025 on 12 February 2026 at around 07:00 CET and will present the results later the same day at 13:30 CET via an audiocast and teleconference. The presentation, led by CEO Johannes Doll alongside the CFO and CMO, underscores the company’s ongoing engagement with investors and analysts ahead of its year-end disclosure, offering stakeholders an opportunity to scrutinize performance in its core inhaled sedation business and gain insight into strategic and operational developments.
The most recent analyst rating on (SE:SEDANA) stock is a Hold with a SEK10.00 price target. To see the full list of analyst forecasts on Sedana Medical AB stock, see the SE:SEDANA Stock Forecast page.
More about Sedana Medical AB
Sedana Medical AB is a Stockholm-headquartered medtech and pharmaceutical company specializing in inhaled sedation for mechanically ventilated intensive care patients, built around its Sedaconda ACD medical device and Sedaconda (isoflurane) pharmaceutical product. Founded in 2005 and listed on Nasdaq Stockholm, the company sells directly in key European markets including Benelux, France, Germany, Great Britain, and Spain, and operates via distributors across the rest of Europe as well as in Asia, Australia, Canada, and South and Central America.
Average Trading Volume: 158,865
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK1.06B
See more data about SEDANA stock on TipRanks’ Stock Analysis page.